Table 3.

Association between DNMT3b and ADH1C polymorphisms and risk of adenomatous and hyperplastic polyps

PolymorphismControls (n)Adenomas
Hyperplastic polyps
Cases (n)OR (95% CI)Cases (n)OR (95% CI)
DNMT3b genotypes
−149C>T
    C/C (ref.)2161671.00 (ref.)531.00 (ref.)
    C/T3002500.93 (0.69-1.26)1061.24 (0.82-1.86)
    T/T1061071.28 (0.88-1.87)351.33 (0.78-2.28)
−283T>C
    T/T (ref.)2351861.00 (ref.)611.00 (ref.)
    T/C2912430.93 (0.69-1.24)1051.34 (0.90-1.98)
    C/C95951.21 (0.82-1.78)271.12 (0.63-1.98)
−579G>T
    G/G (ref.)2391901.00 (ref.)601.00 (ref.)
    G/T2882370.92 (0.69-1.23)1021.33 (0.89-1.97)
    T/T95981.27 (0.87-1.87)311.38 (0.80-2.40)
DNMT3b haplotypes*
    CTG (ref.)56.653.81.00 (ref.)52.71.00 (ref.)
    TCT36.939.81.09 (0.93-1.27)40.31.12 (0.92-1.37)
    Rare6.56.31.03 (0.84-1.24)7.00.90 (0.68-1.17)
ADH1C
    1/1 (ref.)2201771.00 (ref.)741.00 (ref.)
    1/22992511.15 (0.86-1.55)860.88 (0.59-1.30)
    2/2103921.23 (0.83-1.81)331.04 (0.62-1.73)
  • NOTE: Multivariate adjustment for age, sex, smoking (pack-years), alcohol, hormone use (females only), body mass index, caloric intake, fiber intake, folate intake, methionine intake, vitamin B12 intake, vitamin B6 intake, and riboflavin intake.

  • * Percentages rather than total N are reported for haplotypes because they are inferred rather than determined.